Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
65.15 EUR | -1.73% | -21.07% | -32.85% |
06-19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The firm trades with high earnings multiples: 28.42 times its 2024 earnings per share.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.85% | 6.33B | - | ||
+4.98% | 213B | B | ||
+7.44% | 184B | B- | ||
+28.22% | 153B | B- | ||
+33.19% | 113B | A- | ||
+0.84% | 63.66B | A- | ||
+16.51% | 53.53B | B+ | ||
+1.45% | 49.11B | B+ | ||
-4.53% | 38.73B | A | ||
+2.74% | 36.26B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- AFX Stock
- Ratings Carl Zeiss Meditec AG